Search

Your search keyword '"Schittulli F"' showing total 194 results
Start Over Author "Schittulli F"
194 results on '"Schittulli F"'

12. Genetic alterations in hereditary breast cancer

Author

Cipollini, G., Tommasi, S., Paradiso, A., Aretini, P., Bonatti, F., Brunetti, I., Bruno, M., Lombardi, G., Schittulli, F., Sensi, E., Tancredi, M., Bevilacqua, G., and Caligo, M. A.

Published
2004

14. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Author

EBCTCG, Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., Nomura, Y., Sakai, K., Sugimachi, K., Tominaga, T., Uchino, J., Yoshida, M., Haybittle, Jl, Davies, C., Harvey, Vj, Holdaway, Tm, Kay, Rg, Mason, Bh, Forbes, Jf, Wilcken, N., Gnant, M., Jakesz, R., Ploner, M., Yosef, Hma, Focan, C., Lobelle, Jp, Peek, U., Oates, Gd, Powell, J., Durand, M., Mauriac, L., Di Leo, A., Dolci, S., Piccart, Mj, Masood, Mb, Parker, D., Price, Jj, Hupperets, Psgj, Jackson, S., Ragaz, J., Berry, D., Broadwater, G., Cirrincione, C., Muss, H., Norton, L., Weiss, Rb, Abu-Zahra, Ht, Portnoj, Sm, Baum, M., Cuzick, J., Houghton, J., Riley, D., Gordon, Nh, Davis, Hl, Beatrice, A., Mihura, J., Naja, A., Lehingue, Y., Romestaing, P., Dubois, Jb, Delozier, T., Mace-Lesec H, J., Rambert, P., Andrysek, O., Barkmanova, J., Owen, Jr, Meier, P., Howell, A., Ribeiro, Gc, Swindell, R., Alison, R., Boreham, J., Clarke, M., Collins, R., Darby, S., Elphinstone, P., Evans, V., Godwin, J., Gray, R., Harwood, C., Hicks, C., James, S., Mackinnon, E., Mcgale, P., Mchugh, T., Mead, G., Peto, R., Wang, Y., Albano, J., Oliveira, Cf, Gervasio, H., Gordilho, J., Johansen, H., Mouridsen, Ht, Gelman, Rs, Harris, Jr, Henderson, Ic, Shapiro, Cl, Andersen, Kw, Axelsson, Ck, Blichert-Toft, M., Moller, S., Overgaard, J., Overgaard, M., Rose, C., Cartensen, B., Palshof, T., Trampisch, Hj, Dalesio, O., Vries, Ege, Rodenhuis, S., Tinteren, H., Comis, Rl, Davidson, Ne, Robert, N., Sledge, G., Tormey, Dc, Wood, W., Cameron, D., Chetty, U., Forrest, P., Jack, W., Rossbach, J., Klijn, Jgm, Treurniet-Donker, Ad, Putten, Wlj, Costa, A., Veronesi, U., Bartelink, H., Duchateau, L., Legrand, C., Sylvester, R., Hage, Ja, Velde, Cjh, Cunningham, Mp, Catalano, R., Creech, Rh, Bonneterre, J., Fargeot, P., Fumoleau, P., Kerbrat, P., Namer, M., Jonat, W., Kaufmann, M., Schumacher, M., Minckwitz, G., Bastert, G., Rauschecker, H., Sauer, R., Sauerbrei, W., Schauer, A., Schryver, A., Vakaet, L., Belfiglio, M., Nicolucci, A., Pellegrini, F., Sacco, M., Valentini, M., Mcardle, Cs, Smith, Dc, Galligioni, E., Boccardo, F., Rubagotti, A., Dent, Dm, Gudgeon, Ca, Hacking, A., Erazo, A., Medina, Jy, Izuo, M., Morishita, Y., Takei, H., Fentiman, Is, Hayward, Jl, Rubens, Rd, Skilton, D., Graeff, H., Janicke, F., Meisner, C., Scheurlen, H., Fournier, D., Dafni, U., Fountzilas, G., Klefstrom, P., Blomqvist, C., Saarto, T., Margreiter, R., Asselain, B., Salmon, Rj, Vilcoq, Jr, Rodrigo Arriagada, Hill, C., Laplanche, A., Le, Mg, Spielmann, M., Bruzzi, P., Montanaro, E., Rosso, R., Sertoli, MR, Venturini, M., Amadori, D., Benraadt, J., Kooi, M., Velde, Ao, Dongen, Ja, Vermorken, Jb, Castiglione, M., Cavalli, F., Coates, A., Collins, J., Forbes, J., Gelber, Rd, Goldhirsch, A., Lindtner, J., Price, Kn, Rudenstam, Cm, Senn, Hj, Bliss, Jm, Chilvers, Ced, Coombes, Rc, Hall, E., Marty, M., Borovik, R., Brufman, G., Hayat, H., Robinson, E., Wigler, N., Bonadonna, G., Camerini, T., Palo, G., Del Vecchio, M., Formelli, F., Valagussa, P., Martoni, A., Pannuti, F., Cocconi, G., Colozza, A., Camisa, R., Aogi, K., Takashima, S., Ikeda, T., Inokuchi, K., Sawa, K., Sonoo, H., Korzeniowski, S., Skolyszewski, J., Ogawa, M., Yamashita, J., Bonte, J., Christiaens, R., Paridaens, R., Den Boegart, W., Martin, P., Romain, S., Hakes, T., Hudis, Ca, Wittes, R., Giokas, G., Kondylis, D., Lissaios, B., La Huerta, R., Sainz, Mg, Altemus, R., Cowan, K., Danforth, D., Lichter, A., Lippman, M., O Shaughnessy, J., Pierce, Lj, Steinberg, S., Venzon, D., Zujewski, J., Paradiso, A., Lena, M., Schittulli, F., Myles, Jd, Pater, Jl, Pritchard, Ki, Anderson, S., Bass, G., Brown, A., Bryant, J., Costantino, J., Dignam, J., Fisher, B., Redmond, C., Wieand, S., Wolmark, N., Jackson, Im, Palmer, Mk, Ingle, Jn, Suman, Vj, Bengtsson, No, Jonsson, H., Larsson, Lg, Lythgoe, Jp, Kissin, M., Erikstein, B., Hannisdal, E., Jacobsen, Ab, Varhaug, Je, Gundersen, S., Hauer-Jensen, M., Host, H., Nissen-Meyer, R., Blamey, Rw, Mitchell, Ak, Morgan, Dal, Robertson, Jfr, Di Palma, M., Mathe, G., Misset, Jl, Clark, Rm, Levine, M., Morimoto, K., Takatsuka, Y., Crossley, E., Harris, A., Talbot, D., Taylor, M., Di Blasio, B., Ivanov, V., Semiglazov, V., Brockschmidt, J., Cooper, MR, Ueo, H., Falkson, Ci, A Hern, R., Ashley, S., Powles, Tj, Smith, Ie, Yarnold, Jr, Gazet, Jc, Cocoran, N., Deshpande, N., Di Martino, L., Douglas, P., Lindtner, A., Notter, G., Bryant, Ajs, Ewing, Gh, Firth, La, Krushen-Kosloski, Jl, Foster, L., George, Wd, Stewart, Hj, Stroner, P., Malmstrom, P., Moller, Tr, Ryden, S., Tengrup, I., Tennvall-Nittby, L., Carstenssen, J., Dufmats, M., Hatschek, T., Nordenskjold, B., Soderberg, M., Carpenter, Jt, Albain, K., Crowley, J., Green, S., Martino, S., Osborne, Ck, Ravdin, Pm, Glas, U., Johansson, U., Rutqvist, Le, Singnomklao, T., Wallgren, A., Maibach, R., Thurlimann, B., Brenner, H., Hercbergs, A., Yoshimoto, M., Deboer, G., Paterson, Ahg, Meakin, Jw, Panzarella, T., Shan, Y., Shao, Yf, Wang, X., Zhao, Db, Chen, Zm, Pan, Hc, Bahi, J., Reid, M., Spittle, M., Deutsch, Gp, Senanayake, F., Kwong, Dlw, Bianco, Ar, Carlomagno, C., Laurentiis, M., Placido, S., Buzdar, Au, Smith, T., Bergh, J., Holmberg, L., Liljegren, G., Nilsson, J., Seifert, M., Sevelda, P., Zielinsky, Cc, Buchanan, Rb, Cross, M., Royle, Gt, Dunn, Ja, Hills, Rk, Lee, M., Morrison, Jm, Spooner, D., Litton, A., Chlebowski, Rt, Caffier, H., Faculteit Medische Wetenschappen/UMCG, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Early Breast Cancer Trialists' Collaborative, Group, DE LAURENTIIS, Michelino, and DE PLACIDO, Sabino

Subjects
Oncology, medicine.medical_specialty, Antineoplastic Agents, Hormonal, DEATHS, Ovariectomy, Antineoplastic Agents, Breast Neoplasms, Aged, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Cause of Death, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Ovary, Randomized Controlled Trials as Topic, Receptors, Estrogen, Survival Rate, Tamoxifen, Medicine (all), Breast cancer, MammaPrint, Internal medicine, Receptors, medicine, Chemotherapy, TAMOXIFEN, skin and connective tissue diseases, Survival rate, Adjuvant, Gynecology, Hormonal, medicine.diagnostic_test, Oncotype DX Breast Cancer Assay, business.industry, General Medicine, medicine.disease, Estrogen, Neoplasm Recurrence, Local, Hormonal therapy, Oncotype DX, business, medicine.drug, Epirubicin
Abstract

Background Quinquennial overviews (1985–2000) of the randomised trials in early breast cancer have assessed the 5 year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxorubicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modern aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50–69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0·0001 for recurrence, 2p For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age ( These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1–2 years of tamoxifen versus none (33 000); and about 5 years versus 1–2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.

Published
2005

18. The 76-Gene Signature Defines High-Risk Patients That Benefit from Adjuvant Tamoxifen Therapy.

Author

Zhang, Y., primary, Sieuwerts, A., additional, McGreevy, M., additional, Graham, C., additional, Cufer, T., additional, Paradiso, A., additional, Harbeck, N., additional, Span, P., additional, Hicks, D., additional, Crowe, J., additional, Tubbs, R., additional, Thomas, B., additional, Lyons, J., additional, Sweep, F., additional, Schmitt, M., additional, Schittulli, F., additional, Golouh, R., additional, Talantov, D., additional, Wang, Y., additional, and Foekens, J., additional

Published
2009
Full Text
View/download PDF

19. Randomized phase III trial of adjuvant epicirubicin (E) followed by cyclophosphamide, methotrexate, and fluorouracil (CMF) or CMF followed by E in patients with N- or ≤ 3 N+ rapidly proliferating breast cancer (RPBC)

Author

Amadori, D., primary, Schittulli, F., additional, Paradiso, A., additional, Scarpi, E., additional, Sismondi, P., additional, Ravaioli, A., additional, Rocca, A., additional, Maltoni, R., additional, Serra, P., additional, and Silvestrini, R., additional

Published
2009
Full Text
View/download PDF

33. HER-2/neu in bladder carcinoma

Author

Tommasi, S, primary, Ditonno, P, additional, Sisto, M, additional, Paradiso, A, additional, Gentile, A, additional, Ricco, R, additional, Schittulli, F, additional, and Jacobellis, U, additional

Published
1996
Full Text
View/download PDF

35. Preliminary Clinical Evaluation of free/total PSA Ratio by the IMMULITE® system

Author

Correale, M., primary, Pagliarulo, A., additional, Donatuti, G., additional, Sturdà, F., additional, Capobianco, A.M.L., additional, Stigliani, V., additional, Rizzello, M., additional, Circhietta, S., additional, Pignatelli, F., additional, Leone, L., additional, Frusciante, V., additional, Modoni, S., additional, and Schittulli, F., additional

Published
1996
Full Text
View/download PDF

46. Tamoxifene (TAM) and primary breast cancer in old women

Author

Mustacchi, G., primary, Mansutti, M., additional, Milani, S., additional, Pluchinotta, A., additional, Farris, A., additional, Scanni, A., additional, Maiorino, L., additional, Santoro, A., additional, Traina, A., additional, Schieppati, G., additional, Malloci, A., additional, Zadro, A., additional, D'Aiuto, G., additional, Parisi, V., additional, Capasso, I., additional, Villa, E., additional, Fosser, V., additional, Garattini, P., additional, Schittulli, F., additional, Gambrosier, P., additional, De Fabiani, E., additional, Caciotto, C., additional, and Lombardi, M., additional

Published
1990
Full Text
View/download PDF

47. Breast Cancer Estrogen and Progesterone Receptors: Associations with Patients' Clinical and Epidemiologic Characteristics

Author

Fossati, R., Alexanian, A.A., Liberati, A., Marsoni, S., Monferroni, N., Nicolucci, A., Parazzini, F., Giganti, M., Piffanelli, A., Ghezzi, P., Magnanini, S., Rinaldini, M., Berardi, F., Di Biagio, G., Testore, F., Tavoni, N., Palmieri, D., Schittulli, F., Pedicini, T., Fumagalli, M., Gritti, G., Braga, M., Marini, G., Zamboni, A., Cosentino, D., Epifani, C., Scognamiglio, G., Perroni, D., Peradotto, F., Saba, V., Indelli, M., Santini, A., Isa, L., Scapaticci, R., Aitini, E., Gavazzini, G., Smerieri, F., Lomonaco, I., Nascimben, O., Locatelli, E., Monti, M., Ghislandi, E., Gottardi, O., Majno, M., Poma, C., Pluchinotta, A., Armaroli, L., Confalonieri, C., Viola, P., Sisto, R., Buda, F., Plaino, R., Galletto, L., Trolli, B., Biasio, M., Rolfo, A., Vaudano, G., Giolito, M.R., Scoletta, G., Ambrosini, G., Busana, L., Molteni, M., and Richetti, A.

Abstract

A total of 1095 patients with operable breast cancer and en-rolled in a randomized clinical trial were analysed for estrogen (ER) and progesterone (PgR) receptor content of their primary tumor, and the relationships between steroid receptor status and several epidemiologic characteristics were studied. The proportion of ER+ and median ER levels increased with age: compared to women younger than 40, those aged 66 or more were approximately three times more likely to have an ER+ tumor (OR = 3.0, 95% C.I. = 1.6–5.7). This difference tended to be more marked after comparison between patients with ER > 100 fmol/mg protein and ER- within the same age groups: OR = 7.04, 95 % C.I. = 2.89–17.12. No association emerged between age and PgR. ER status and concentrations were independent of menopausal status after adjustment for age, whereas the proportion of PgR+ and PgR levels were significantly lower in postmenopausal patients of the same age. The distribution of ER and PgR profiles was similar in relation to family history of breast cancer, reproductive events and other selected epidemiologic characteristics of the patients.

Published
1991
Full Text
View/download PDF

48. Infiltrating cribriform carcinoma of the breast. A clinico-pathologic and immunohistochemical study of 5 cases

Author

Marzullo, F., Zito, F. A., Marzullo, A., Labriola, A., Schittulli, F., Giulio Gargano, Girolamo, R., and Colonna, R.

Subjects
Aged, 80 and over, Receptors, Estrogen, Humans, Breast Neoplasms, Female, Adenocarcinoma, Child, Receptors, Progesterone, Immunohistochemistry, Aged
Abstract

Clinical and pathological features of five cases of infiltrating cribriform carcinoma (ICC) of the breast observed between 1990 and 1994 are reported. Using histological criteria by Page et al., three cases of pure ICC and two cases of mixed ICC were identified. In the mixed forms, the cribriform component made up about 80% of the neoplasm. After clinical follow-up, from one to five years long, no relapses, axillary lymph nodes or distant metastases were found, even in two cases with very large neoplasms (20 cm and 10 cm, respectively). This report confirms that this type of carcinoma has a very favorable prognosis, especially pure and mixed forms with a predominant cribriform component. Clinical and histological features make ICC a peculiar form of breast carcinoma.

49. Multi-center validation of the 76-gene prognostic signature in lymph node negative (LNN) primary breast cancer

Author

Foekens, J. A., Atkins, D., Sweep, C. G. J., Harbeck, N., Paradiso, A., Cufer, T., Eppenberger, S., Daxenbichler, G., Kotzsch, M., Sieuwerts, A. M., Talantov, D., Timmermans, M., Paul Span, Tjan-Heijnen, V. C. G., Specht, K., Mangia, A., Wight, E., Angerer, J., Zito, A. F., Hoefler, H., Berns, E. M. J., Golouh, R., Barreton, G., Schittulli, F., Schmitt, M., Beex, L. V. A., Klijn, J. G. M., Wang, Y., and Erasmus, M. C.

50. BRCA1 expression and molecular alterations in familial breast cancer

Author

Anita Mangia, Chiriatti, A., Tommasi, S., Menolascina, F., Petroni, S., Zito, F. A., Simone, G., Schittulli, F., and Paradiso, A.

Subjects
616 - Patología. Medicina clínica. Oncología, Breast cancer, endocrine system diseases, Family history, skin and connective tissue diseases
Abstract

The aim of the study was to evaluate the performance of immunohistochemical MS110 expression in a series of familial and sporadic breast cancer patients. An immunohistochemical study was performed on TMA samples from 93 sporadic and 94 familial breast cancer patients with (7/94) and without BRCA1 germline mutations. BRCA1 protein expression level was evaluated using the monoclonal MS110 antibody. Immunohistochemistry, performed on TMA samples, showed positive nuclear staining for BRCA1 in 34 sporadic and 37 familial breast tumours, respectively. All the tumours from patients carrying BRCA1 mutations showed complete loss of both BRCA1 and ERa expression, regardless of the type of mutation. The percentage of MS110 positive cases was significantly lower in mutated versus wild type BRCA1 familial cases (p=0.02) while the percentage of patients with higher ERa expression was significantly lower in BRCA1- mutated versus BRCA1-wild type familial patients (p=0.05). Interestingly, the presence of the E1038G polymorphism in BRCA1 exon 11 was significantly associated with protein expression (p=0.029). The frequency of MS110 negative cases also detected in BRCA1-wild type tumours, points to the inability of the BRCA1 IHC expression in discriminating between familial and sporadic breast cancer.

Catalog

Books, media, physical & digital resources
See catalog results